US Securities Regulator Probes Illumina Over Grail Deal

The SEC has begun an investigation into Illumina's $7.1 billion acquisition of cancer detection test maker Grail, the gene sequencing company said in a regulatory filing.
Reuters Health Information

source https://www.medscape.com/s/viewarticle/995375?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?